Regeneron Pharmaceuticals Inc

REGN

NASDAQ. Currency in USD

721.10 -2.07 ( -0.29% )

Real time prices: December 19

Market Cap.
78.53B
Beta (5Y monthly)
0.21
Price/Earnings
13.64
EPS (TTM)
56.12
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
459,144
1y Target Est.
802.25
Day's Range
713.00
-
726.15
52 Week's Range
538.01
-
779.00

Historical Summary

Performance
EPS growth
Share Buybacks

About Regeneron Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.regeneron.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
105.72M
Employees
10915
Address
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Latest news

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of...
By Zacks Investment Research - 6 weeks ago

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth
Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line....
By Zacks Investment Research - 7 weeks ago

2 Best Biotech Stocks to Buy Right Now
2 Best Biotech Stocks to Buy Right Now

Demand for medicines and vaccines has nowhere to go but up over the long run.
By The Motley Fool - 7 weeks ago

Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis
Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult...
By Zacks Investment Research - 7 weeks ago

Regeneron (REGN) Presents Positive Data on MM and FL Drugs
Regeneron (REGN) Presents Positive Data on MM and FL Drugs

Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.
By Zacks Investment Research - 7 weeks ago

This fund beats the S&P 500 by using just 75 of its components. Here's how it works.
This fund beats the S&P 500 by using just 75 of its components. Here's how it works.

A combination of quality and lower prices has worked well through bull and bear markets...
By MarketWatch - 7 weeks ago

Will This Potential Approval Be a Winner for Sanofi's Shareholders?
Will This Potential Approval Be a Winner for Sanofi's Shareholders?

Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in...
By The Motley Fool - 8 weeks ago

This fund beats the S&P 500 by using just 75 of its components. Here's how it works.
This fund beats the S&P 500 by using just 75 of its components. Here's how it works.

A combination of quality and lower prices has worked well through bull and bear markets...
By MarketWatch - 8 weeks ago